KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Ionis Pharmaceuticals (IONS) over the last 13 years, with Sep 2025 value amounting to $110.7 million.

  • Ionis Pharmaceuticals' Change in Accured Expenses rose 950.60% to $110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 419.96%. This contributed to the annual value of -$43.0 million for FY2024, which is 331.78% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Change in Accured Expenses is $110.7 million, which was up 453.97% from $20.0 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $110.7 million during Q3 2025, with a 5-year trough of -$46.2 million in Q1 2024.
  • In the last 3 years, Ionis Pharmaceuticals' Change in Accured Expenses had a median value of $7.0 million in 2024 and averaged $5.7 million.
  • Examining YoY changes over the last 5 years, Ionis Pharmaceuticals' Change in Accured Expenses showed a top increase of 6,933.89% in 2022 and a maximum decrease of 429.22% in 2022.
  • Ionis Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $6.5 million in 2021, then rose by 29.92% to $8.4 million in 2022, then surged by 407.21% to $42.8 million in 2023, then plummeted by 133.51% to -$14.3 million in 2024, then spiked by 950.60% to $110.7 million in 2025.
  • Its Change in Accured Expenses was $110.7 million in Q3 2025, compared to $20.0 million in Q2 2025 and -$43.0 million in Q1 2025.